Optogenetic gene therapy improves light sensitivity in 7 of 10 people blinded by retinitis pigmentosa
Optogenetic gene therapy restored some vision to people blinded by retinitis pigmentosa in a small NEJM trial. Seven of 10 participants improved in light sensitivity, Science News reported, though the goggle-aided sight let none of them read words or see faces.
The Scientist · Science desk
What happened
- Researchers injected genes for ChrimsonR, a light-sensitive algae protein, into each participant's worse-seeing eye, making its retinal ganglion cells respond to amber light.
- Custom goggles carry a camera that detects changes in brightness and projects them onto the retina as pulses of amber light.
- Four of the eight participants who completed behavioral testing could find a doorway or follow a line while wearing the goggles.
Why it matters
- What's now possible capability Outside the subset whose mutation qualifies for existing gene therapy, retinitis pigmentosa care only slows the loss; moving light sensing into surviving ganglion cells gives the rest a candidate route to regaining some function.
- What it costs cost The functional gains were measured with custom goggles on, so the treatment as tested is a gene injection paired with a camera device, and a patient needs both to benefit.
- What it limits constraint Patients whose retina-to-brain connection is damaged fall outside the approach, so eligibility will depend on the optic nerve as well as the retina.
Next story · Science · 6d ago
Optogenetic gene therapy is safe in 10 people blinded by retinitis pigmentosa, NEJM trial findsConfirmed2 publishers
The 7-of-10 figure counts improved light sensitivity [1]. The behavioral test is a closer proxy for usable sight, and it ran on fewer people. Four successes out of eight tested [12] is half of that group [19] and 40 percent of the ten treated [20]. Two participants did not complete behavioral testing [21]. The news reports do not say why, and they do not describe a control group.
With ten people, each participant moves the response rate by 10 percentage points [16], so the 70 percent is a rough estimate [17]. In my view it is still enough to call the result repeatable. The study it builds on was a single case: a 2021 report of one blind man who could see and count objects [7].
The design works around the damage instead of repairing it. Retinitis pigmentosa kills the retina's light-sensing cells [2], so the therapy gives light sensitivity to the ganglion cells that normally relay visual signals to the brain [8]. Everything past those cells still has to work. The approach needs a working optic nerve, according to coauthor José-Alain Sahel, an ophthalmologist at the University of Pittsburgh [14]. When the retina's connection to the brain is damaged, it cannot restore vision [14].
Botond Roska, a neuroscientist at the Institute of Molecular and Clinical Ophthalmology Basel, described the result as a proof of concept that optogenetics can bring back some visual activity and object sensitivity [9][15]. His group hopes to work on reading and faces next [13].
The people this is aimed at are usually diagnosed in childhood or early adolescence and are often legally blind by young adulthood, STAT reported [4]. The paper appeared in the New England Journal of Medicine on Wednesday, October 7 [1][6], two days after pioneering optogenetics work won the 2026 Nobel Prize in Physiology or Medicine [3][18].
What to watch
- A full trial report explaining why two of the ten participants missed behavioral testing and whether any untreated comparison was used.
- Whether Roska's group shows reading or face recognition in a later cohort, a goal no participant in this trial reached.
- Whether light sensitivity in the treated eyes holds up over longer follow-up.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence50
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence55
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
The treatment improved seven of 10 people's light sensitivity, researchers reported October 7 in the New England Journal of Medicine.
- [2]
Participants had blindness caused by retinitis pigmentosa, a genetic disease that progressively kills off light-sensing cells in the retina.
- [3]
Pioneering work on optogenetics won the 2026 Nobel Prize in Physiology or Medicine on October 5.
- [4]
Retinitis pigmentosa is generally diagnosed in childhood or early adolescence; patients gradually lose peripheral and night vision and often become legally blind by young adulthood.
- [5]
Except for a subset of patients with a specific genetic mutation who can be treated with gene therapy, there is no cure for retinitis pigmentosa; cases are managed by slowing degeneration and preserving remaining vision.
- [6]
The small trial's paper was published on Wednesday in the New England Journal of Medicine; optogenetics had just been recognized with a Nobel Prize.
- [7]
The findings build on a 2021 report that the same approach helped one blind man see and count objects.
- [8]
The treatment uses optogenetics; rather than repair the retina's damaged light detectors, it gives light sensitivity to retinal ganglion cells that normally relay visual signals to the brain.
- [9]
"This is a proof of concept that optogenetics can bring back some visual activity [and] object sensitivity."
- [10]
As in the 2021 study, researchers injected genetic instructions for ChrimsonR, a light-sensitive protein derived from algae, into participants' worse-seeing eye, making retinal ganglion cells in that eye sensitive to amber light.
- [11]
A camera in custom goggles detected changes in brightness in front of the participant, and the goggles projected those changes onto the retina as pulses of amber light, activating the treated cells.
- [12]
Four of the eight study participants who completed behavioral testing after treatment were able to find a doorway or follow a line while wearing the goggles.
- [13]
No patient gained the ability to read visual words or see faces; Roska and colleagues hope to tackle that next.
- [14]
The approach requires a working optic nerve to carry signals to the brain and cannot restore vision when the retina's connection to the brain is damaged, says study coauthor José-Alain Sahel, an ophthalmologist at the University of Pittsburgh.
- [15]
Botond Roska is a neuroscientist at the Institute of Molecular and Clinical Ophthalmology Basel in Switzerland.
- [16]
In a 10-person cohort, each participant accounts for 10 percentage points of any response rate.
- [17]
The light-sensitivity response rate was 70 percent.
- [18]
The NEJM paper appeared two days after the optogenetics Nobel Prize was announced.
- [19]
Half of the participants who completed behavioral testing could find a doorway or follow a line.
- [20]
Forty percent of the ten treated participants demonstrated doorway-finding or line-following in behavioral testing.
- [21]
Two of the ten treated participants did not complete behavioral testing.
Sources
2 independent publishers whose own reporting we read for this story.
- sciencenews.orgGene therapy and special goggles give some blind people limited sight
1 article · October 7, 2026
- statnews.comSTAT+: In small trial, optogenetics restores some vision lost to retinitis pigmentosa
1 article · October 7, 2026
Topics and entities
Entities
- New England Journal of Medicine
- University of Pittsburgh
- Nobel Prize in Physiology or Medicine
- Institute of Molecular and Clinical Ophthalmology Basel
- José-Alain Sahel